KATRINA BUXBAUM: Open Payments
NPI 1710266242 · ARCADIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$290 in 10 payments from 10 companies in 2025. Trend: 2023 $97 · 2024 $18 · 2025 $290
Food & beverage: $290
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $39 |
| Madrigal Pharmaceuticals | 1 | $38 |
| Echosens North America, Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $32 |
| TerSera Therapeutics LLC | 1 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| ABBVIE INC. | 1 | $24 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| Novo Nordisk Inc | 1 | $22 |
| Gilead Sciences, Inc. | 1 | $20 |
Products named: XIFAXAN, REZDIFFRA, Fibroscan, Xermelo, IQIRVO, MAVYRET, Livmarli.
Industry payments across CA — which companies pay providers there.
